About the Authors

Kathrin Malejko

Contributed equally to this work with: Kathrin Malejko, Patrick Weydt

Affiliation Department of Psychiatry, Ulm University, Leimgrubenweg 12–14, 89522, Ulm, Germany

Patrick Weydt

Contributed equally to this work with: Kathrin Malejko, Patrick Weydt

Affiliation Department of Neurology, Ulm University, Oberer Eselsberg 45, 89081, Ulm, Germany

Sigurd D. Süßmuth

Affiliation Department of Neurology, Ulm University, Oberer Eselsberg 45, 89081, Ulm, Germany

Georg Grön

Affiliation Department of Psychiatry, Ulm University, Leimgrubenweg 12–14, 89522, Ulm, Germany

Bernhard G. Landwehrmeyer

Affiliation Department of Neurology, Ulm University, Oberer Eselsberg 45, 89081, Ulm, Germany

Birgit Abler

birgit.abler@uni-ulm.de

Affiliation Department of Psychiatry, Ulm University, Leimgrubenweg 12–14, 89522, Ulm, Germany

Competing Interests

K.M., P.W., G.G. and B.A. report no disclosures. S.D.S has received funding for travel from Ipsen and Novartis and received honoraria for lectures from Commonwealth SerumLaboratories (CSL) Behring and Bayer. B.G.L. has received consulting fees from Siena Biotech, Aop-Orphan pharmaceuticals, Teva Pharmaceutical Industries, GlaxoSmithKline, Bayer Pharma Aktiengesellschaft (AG), Ipsen Pharma and research support from the European Commission, Cure Huntington Disease Initiative (CHDI) Foundation, Medivation, NeuroSearch, Novartis, Medesis Pharma and Amarin Pharma. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: KM PW BA. Performed the experiments: KM PW BA. Analyzed the data: KM GG BA. Wrote the paper: KM PW BA. Patient Recruitment: SDS BGL.